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Eﬀ ect on the incidence of pneumonia of vitamin D 
supplementation by quarterly bolus dose to infants in Kabul: 
a randomised controlled superiority trial
Semira Manaseki-Holland, Zabihullah Maroof, Jane Bruce, M Zulf Mughal, Mohammad Isaq Masher, Zulﬁ qar A Bhutta, Gijs Walraven, 
Daniel Chandramohan
Summary 
Background Vitamin D has a role in regulating immune function, and its deﬁ ciency is a suggested risk factor for 
childhood pneumonia. Our aim was to assess whether oral supplementation of vitamin D₃ (cholecalciferol) will 
reduce the incidence and severity of pneumonia in a high-risk infant population.
Methods We did a randomised placebo-controlled trial to compare oral 100 000 IU (2·5 mg) vitamin D₃ with placebo 
given to children aged 1–11 months in Kabul, Afghanistan. Randomisation was by use of a computer-generated list. 
Vitamin D or placebo was given by ﬁ eldworkers once every 3 months for 18 months. Children presenting at the study 
hospital with signs of pneumonia had their diagnosis conﬁ rmed radiographically. Our primary outcome was the ﬁ rst 
or only episode of radiologically conﬁ rmed pneumonia. Our analysis was by intention to treat. This study is registered 
with ClinicalTrials.gov, number NCT00548379.
Findings 1524 children were assigned to receive vitamin D₃ and 1522 placebo. There was no signiﬁ cant diﬀ erence 
between the incidence of ﬁ rst or only pneumonia between the vitamin D (0·145 per child per year, 95% CI 
0·129–0·164) and the placebo group (0.137, 0·121–0·155); the incidence rate ratio was 1·06 (95% CI 0·89–1·27). 
From 652 children during ﬁ ve separate periods of testing serum calcifediol, only one child in each of two testing 
periods had results greater than 375 nmol/L in the intervention group—a toxic level.
Interpretations Quarterly bolus doses of oral vitamin D₃ supplementation to infants are not an eﬀ ective intervention 
to reduce the incidence of pneumonia in infants in this setting.
Funding Wellcome Trust and British Council.
Introduction
Afghanistan has the third highest mortality of children 
younger than 5 years in the world (257 per 1000 livebirths); 
a leading cause of this is pneumonia. Two hospital-based 
case-control studies in Ethiopia1 and India2 suggest that 
vitamin D deﬁ ciency might substantially increase the 
risk of severe pneumonia in children. Our systematic 
review identiﬁ ed one randomised placebo controlled 
trial3 relating pneumonia or lower respiratory infections 
to vitamin D deﬁ ciency supplementation in young 
children. This trial of 100 000 IU (2·5 mg) vitamin D₃ 
(cholecalciferol) supplementation along with antibiotic 
treatment of children younger than 3 years with clinically 
diagnosed pneumonia in Kabul showed no diﬀ erence in 
the time to recovery between the groups. However, the 
risk of repeated pneumonia in the subsequent 3 months 
was 13% (relative risk [RR] 0·78, 95% CI 0·64–0·94; 
p=0·01) lower in the vitamin D₃ compared with the 
placebo group.3 Other more recent studies assessing 
diﬀ erent outcomes in children or adults have conﬂ icting 
ﬁ ndings on the eﬀ ectiveness of vitamin D.
There is growing evidence of the vitamin D parancrine 
system enhancing innate immunity:4 the activation of Toll-
like receptors on monocytes and macrophages by micro-
bial pathogens results in increased expression of CYP27B1 
and vitamin D receptor (VDR) genes within these cells. In 
the presence of adequate concentrations of calcifediol 
(25-hydroxyvitamin D), CYP27B1 leads to an increase 
synthesis of intracellular calcitriol (1,25-di hydroxy-
vita min D). The binding of this to vitamin D receptors in 
turn results in increased intracellular formation of anti-
microbial compounds, such as cathelicidins.5 The 
generation of intracellular anti microbial compounds is 
impaired in patients who are vitamin D deﬁ cient (ie, low 
serum concentrations of calcifediol). It has been suggested 
that vitamin D might be used in the treatment of oppor-
tunistic and antibiotic-resistant infections.
There is debate between investigators regarding con-
cen trations that relate to optimum stores of vitamin D in 
the body. In children, serum calcifediol concentrations 
should be maintained at 50 nmol/L (20 ng/mL) or greater 
for skeletal beneﬁ ts.6 Vitamin D deﬁ ciency rickets in 
children younger than 5 years is an endemic problem in 
developing countries, ranging from 5–45%, even where 
sunlight is abundant,1,2,7,8 and has also re-emerged in 
some developed countries.7,9
In people, the main source of vitamin D is through the 
action of ultraviolet B radiation on 7-dehydrocholesterol 
in the skin, with small amounts derived from dietary 
sources. In Afghanistan, dietary intake of vitamin D is 
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low10 and exposure of women to sunlight is limited by the 
widespread use of the burqa. Therefore, breastmilk, a 
normally poor source of vitamin D,11 becomes even more 
deﬁ cient. Furthermore, the common practice of swaddling 
infants might reduce exposure to sunlight.2 Thus young 
children are at a high risk of vitamin D deﬁ ciency. A cross-
sectional survey during the high-risk winter months in 
2005 showed that greater than 95% of children younger 
than 5 years in a socioeconomically deprived part of Kabul 
had serum calcifediol levels of less than 37·5 nmol/L.12
On the basis of ﬁ ndings that vitamin D is an immuno-
modulator, that deﬁ ciency is a risk factor for pneumonia, 
and that quarterly supplementation had better compliance 
than daily or weekly supple mentation,13,14 we aimed to test 
the hypothesis that quarterly 100 000 IU vitamin D 
supplementation would reduce the incidence of radio-
logically conﬁ rmed pneumonia by 35% in our study 
population. Our secondary hypotheses were that supple-
mentation would reduce all pneumonias (radio logically 
conﬁ rmed or clinically deﬁ ned), repeat episodes of 
pneumonia, hospital admissions, and all cause mortality. 
We selected infants from inner-city Kabul because we 
knew the prevalence of vitamin D deﬁ ciency12 and 
incidence of pneumonia3,15 were high.
Methods
Participants
Between Nov 4 and Dec 4, 2008, we did a community 
based randomised placebo-controlled superiority trial in 
Kabul, Afghanistan, within the catchment area of the 
Maiwand Teaching Hospital, which serves an inner-city 
population. Follow up ended in May, 2009. The children 
we enrolled into our study largely came from ﬁ ve of the 
18 socio economically deprived inner-city districts. We 
identiﬁ ed households with young children with detailed 
maps and advice from staﬀ  of the Agha Khan Trust for 
Culture, a non-governmental organisation working in 
the region. Furthermore, the study ﬁ eld-supervisors 
mapped the region independently to verify the accuracy 
of the maps of the Agha Khan Trust for Culture, and 
during recruitment they visited every house in the 
mapped region to identify families with young children.
20 pairs of female ﬁ eldworkers visited every home 
starting from streets closest to the hospital and radiating 
out until we reached our required sample size. Those 
homes where the carer or infant was absent were revisited 
again within 4 weeks of the recruitment period. Our 
inclusion criteria were infants aged 1–11 months and 
living in our study region. Our exclusion criteria were 
families expecting to move to another town within 
18 months, diagnosis of rickets or treatment with 
vitamin D in the previous 3 months, and clinical 
diagnosis of Kwashiorkor or Marasmus. The ﬁ eldworkers 
obtained written informed consent from the mother, 
father, or another senior family member before 
recruitment; allocated the unique identiﬁ cation number 
(sequentially); and gave the ﬁ rst dose of vitamin D₃ or 
placebo. Children with vomiting were excluded 
temporarily and enrolled 2 weeks later after recovery.
Thumbprint or signature consent was obtained from the 
child’s parents (mother and father if in Kabul or another 
family member responsible for the child) at home if the 
child met our study criteria and after either the parent read 
the Dari consent form or it was explained to him or her by 
the ﬁ eldworker. Our study was approved by the ethics and 
review board of the Ministry of Public Health of Afghanistan 
(reference 422328; issued May 12, 2007) and the ethics 
committee of the London School of Hygiene and Tropical 
Medicine (application number 5117; issued May 29, 2008). 
Randomisation and masking
An independent statistician (Shabbar Jaﬀ ar, London 
School of Hygiene and Tropical Medicine, London, UK) 
randomised unique identiﬁ cation numbers individually 
in ﬁ xed blocks of 20 to the vitamin D₃ or placebo group 
by use of a random number generator with the SAS 
routine. By use of the randomisation list, a pharmacist in 
the Department of Pharmacy, Aga Khan University 
Hospital, Karachi prepared 100 000 IU (2·5 mg) of 
vitamin D₃ (cholecalciferol) in olive oil (Sinochem Ningbo 
Laboratory, China) or placebo (olive oil) in sealed 2 mL 
plastic syringes labelled with the unique identiﬁ cation 
numbers. The vitamin D3 and the placebo were the same 
colour (pale yellow), taste, and quantity (0·5 mL) and 
therefore the study staﬀ  and the families did not know to 
which group the children were assigned. Fieldworkers 
allocated children to randomisation groups during 
recruitment and gave vitamin D or placebo.
Procedures
We chose a quarterly supplementation regimen because 
in routine programme conditions a quarterly regimen is 
likely to have better adherence than a daily regimen,13,14 
and has been shown to be eﬀ ective at maintaining the 
serum vitamin D concentration within normal ranges 
for 2–3 months in a French high-risk infant population.16 
The syringes containing vitamin D or placebo were 
stored in conditions recommended by the manu-
facturer—a dry cool environment—between 2 and 
24 weeks before administration.
We provided each child with an identiﬁ cation card, 
which included a photograph of the child, to enable easy 
access to outpatient and out-of-hours paediatric services 
at the study hospital. We encouraged families to bring 
their children to the study hospital for any illness for 
which quality treatment was oﬀ ered free of charge. Four 
experienced paediatricians and 30 female ﬁ eldworkers 
(medical students, nurses, midwives, or community 
health workers) were rigorously trained in our study 
protocols, the Integrated Management of Childhood 
Illnesses strategy, and the assessment of signs and 
symptoms required by our study. The quality of clinical 
assessment in the clinics and during home visits was 
monitored weekly by study supervisors.
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The ﬁ eldworkers followed up the children every 2 weeks 
until June, 2009, to obtain background information, 
assess illness (symptom history and examination of chest 
in-drawing, body temperature [Thermoval Classic 
Hartmann digital thermometer], signs of dehydration by 
skin pinching, respiratory rate count over 1 min with a 
stopwatch), and to refer to the study hospital if needed. 
Respiratory rate and anthropomorphic data were collected 
twice and we used the mean values in our analysis.
All children clinically diagnosed with pneumonia were 
oﬀ ered free chest radiographs taken by radiographers 
trained by a WHO trainer. The masked radiographs were 
read by two independent paediatric radiologists (based at 
the Acute Respiratory Infections Unit of the Pakistan 
Institute of Medical Sciences), experienced in reading 
paediatric chest radiographs from WHO vaccine trials, 
with WHO proformas for standardised interpretation of 
paediatric chest radiographs for the diagnosis of pneu-
monia.17 In case of disagreement, radiographs were read 
by a third independent radiologist and most decisions 
were accepted. We ascertained causes of death through 
scrutiny of hospital notes, and verbal autopsy interviews 
with the WHO standard questionnaire and review of the 
interview data by two physicians independently.
We deﬁ ned clinical pneumonia as a history of cough 
plus increased respiratory rate for age, chest in-drawing, 
or any danger sign (ie, not drinking or breastfeeding, 
convulsion, vomiting, lethargic or unconscious, stridor 
in a calm child). We deﬁ ned severe pneumonia as cough 
plus chest in-drawing and very severe diseases as cough 
plus any danger signs. Our primary endpoint was the 
ﬁ rst episode of pneumonia from the time of enrolment 
conﬁ rmed by chest radiograph (consolidation or 
inﬁ ltrates). We deﬁ ned as a new episode of pneumonia 
an episode happening 15 days or longer after the ﬁ rst. We 
judged an episode happening within 14 days to be 
continuation of the previous episode.
We collected venous blood samples from randomly 
selected blocks of children on the basis of the assumption 
that each block had an equal number of children from 
the vitamin D₃ and placebo groups. This was to ascertain 
calcifediol serum concentrations 1 week after giving the 
ﬁ rst dose in the placebo group (a baseline value for the 
whole population) as well as early concentrations after 
the ﬁ rst vitamin D supplementation in the intervention 
group (70 in placebo and 69 in intervention groups). We 
also collected samples at other times (appendix) from a 
diﬀ erent set of randomly selected children to check 
ﬂ uctuations in serum concentrations. We stored the 
serum samples at –20°C and analysed them at the end of 
our study with IDS-iSYS Multi-Discipline Automated 
Chemiluminescent assay (Immunodiagnostic Systems 
Ltd, Tyne and Wear, UK) at the Manchester Royal 
Inﬁ rmary, Manchester, UK (Supra-Regional Vitamin D 
Reference Laboratories accredited to ISO9001:2000 and 
ISO13485:2003 and participating in the Vitamin D 
Quality Assurance Scheme).
Statistical analysis
We assumed that the incidence of the ﬁ rst or the only 
episode of pneumonia (ﬁ rst episode) in our placebo group 
would be 0·0585 per child per year based on the report that 
the incidence of acute lower respiratory infections in 
developing countries was greater than 0·65 per child per 
year,18 that 12% of these episodes were pneumonia, and 
75% were ﬁ rst episodes. Given that 73% of children had 
vitamin D deﬁ ciency in the study region in 2005,12 and that 
the incidence of pneumonia was ten-times higher in 
See Online for appendix
1522 randomly assigned to placebo group 
and given ﬁrst round of placebo
1494 given second round of placebo
14 excluded
2 did not meet 
inclusion criteria*
12 refused to 
participate†
1452 given third round of placebo
1404 given fourth round of placebo
1330 given ﬁfth round of placebo
2 protocol violations§
1077 given sixth round of placebo
26 lost to follow-up
2 died
41 lost to follow-up
1 died
47 lost to follow-up
1 died
72 lost to follow-up
2 died
252 lost to follow-up
1 died
3060 children assessed for eligibility
1524 randomly assigned to vitamin D group 
and given ﬁrst round of vitamin D
34 lost to follow-up
3 died
1487 given second round of vitamin D
35 lost to follow-up
6 died
1446 given third round of vitamin D
45 lost to follow-up
1 died
1400 given fourth round of vitamin D
4 protocol violations‡
50 lost to follow-up
1350 given ﬁfth round of vitamin D
262 lost to follow-up
1088 given sixth round of vitamin D
1 protocol violation¶
Figure 1: Trial proﬁ le
*One case was a severely malnourished child and another had received high-dose vitamin D within the past 
3 months. †Did not want to be enrolled in the project for reasons such as did not want to go to Maiwand hospital, 
did not want the ﬁ eldworkers to come to their house, and other with no clear reasons. ‡The syringe with code 
number of 2706 was given to the child with study number of 2707, with 1070 to 1084, and with 2393 to 2939. 
§The syringe with code number of 1418 was given to the child with study number of 1814 and with 2335 to 2235. 
¶The syringe with code number of 2215 was given to the child with study number of 2224.
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vitamin D deﬁ cient children than in children without a 
deﬁ ciency in case-control studies1,2 we postulated that there 
would be at least a 35% reduction in pneumonia incidence 
in the vitamin D compared with the placebo group. Thus a 
study with 80% power and 95% signiﬁ cance needed 
22 079 child-months per group (total of 2454 children for 
18 months follow-up). Assuming a 20% loss to follow-up 
and allowing for protocol violations we intended to recruit 
3050 children for 18 months follow-up.
Data were entered into a Microsoft Access database 
(version 2007) and data processing and analysis was done 
in STATA (version 11.0). We compared baseline charac-
teristics and the distribution of our prestated confounders 
for intervention and placebo groups. To assess the 
potential problem of multicollinearity we used Pearsons 
correlation coeﬃ  cient or Cramers V (for paired 
categorical variables). If a child was not seen for more 
than 45 days, at the two weekly visits, or at the hospital, 
they were censored for that period of our study. These 
children could re-enter the study when next seen. We 
calculated person-time at risk for each child up to the date 
a child reached our primary endpoint, was last seen at the 
end of our study, or when censored because they were 
lost to follow-up. For our intention-to-treat analysis we 
included all children randomly assigned to our study 
groups. For our per-protocol analysis we included children 
who in both groups received all doses with an interval 
between the doses of 60 and 120 days and had not violated 
the randomisation codes. We analysed the repeat episodes 
accounting for clustering within individuals. We made 
initial comparisons of time-to-an-episode between the 
two groups with log-rank tests and Kaplan–Meier plots. 
We estimated the incidence rate ratio (RR) for the episodes 
of pneumonia with Cox proportional hazard models. We 
Vitamin D group 
(N=1524)
Placebo group 
(N=1522)
Sex of child
Male 811 (53%) 780 (51%)
Female 713 (47%) 742 (49%)
Child age at recruitment (months)
<2 132 (9%) 111 (7%)
2–5 510 (34%) 537 (35%)
6–12 882 (58%) 874 (57%)
Malnutrition (weight for age Z score)
–1 or greater 812 (53%) 832 (55%)
–2 or greater to less than –1 415 (27%) 399 (26%)
–3 or greater to less than –2 183 (12%) 195 (13%)
Less than –3 87 (6%) 77 (5%)
Missing 27 (2%) 19 (1%)
Breastfeeding at recruitment
Yes 894 (60%) 902 (61%)
No 589 (40%) 580 (39%)
Ever breastfed
Yes 1463 (99%) 1457 (98%)
No 22 (2%) 28 (2%)
Reported child sun exposure up to 2 h
Everyday 473 (35%) 459 (34%)
Greater than 2 days per week 315 (23%) 344 (26%)
Rarely 558 (42%) 547 (41%)
Maternal age at recruitment (years)
Less than 20 98 (6%) 111 (7%)
20–39 1381 (91%) 1352 (89%)
40 or greater 44 (3%) 58 (4%)
Maternal years of formal education
None 951 (62%) 993 (65%)
1–6 272 (18%) 256 (17%)
7–9 301 (20%) 272 (18%)
10–12 and higher education 951 (62%) 993 (65%)
Marital status
Married 1521 (100%) 1519 (100%)
Widowed, separated, or 
divorced
3 (0%) 3 (0%)
(Continues in next column)
Vitamin D group 
(N=1524)
Placebo group 
(N=1522)
(Continued from previous column)
Paternal years of formal education
None 439 (29%) 449 (30%)
1–6 279 (18%) 263 (17%)
7–9 250 (16%) 256 (17%)
10–12 and higher education 514 (34%) 541 (36%)
Number of indoor smokers in household
0 900 (66%) 889 (65%)
1 or more 459 (30%) 476 (31%)
Indoor air pollution*
High pollution 649 (48%) 668 (49%)
Medium pollution 350 (26%) 332 (24%)
Low or no pollution 360 (27%) 365 (27%)
Number of people sleeping per room
Two or fewer 223 (15%) 238 (16%)
Three to four 508 (34%) 519 (35%)
More than four 627 (42%) 601 (40%)
Father’s ethnic origin (family ethnic origin)
Tajik 1063 (70%) 1074 (71%)
Pashton 352 (23%) 336 (22%)
Uzbek 27 (2%) 21 (1%)
Hazara 62 (4%) 74 (5%)
Other 19 (1%) 16 (1%)
Do not know 1 (0%) 1 (0%)
Socioeconomic status†
Poorest 254 (17%) 235 (16%)
Very poor 226 (15%) 227 (15%)
Less poor 226 (15%) 247 (16%)
Least poor 262 (17%) 266 (18%)
Data are n (%). *On the basis of the type of heating device, the fuel used for heating 
in the winter, and hours the heating devices were used on average in 24 h in the 
past week. †Based on principle component analysis by use of the household assets. 
Table 1: Baseline characteristics of trial children and their families
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assessed violation of the proportionality assumption with 
Schoenfeld residuals. This study is registered with 
ClinicalTrials.gov, number NCT00548379.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. By the end of our trial 
2616 of the 3046 recruited children were present in our 
study and 17 had died. The mortality rate in our study 
cohort was 4·2 per 1000 child years (95% CI 2·4–6·7): 
4·2 per 1000 child years (2·4–6·7; ten cases) in our 
vitamin D group and 3·4 per 1000 child years (1·3–7·1; 
seven cases) in our placebo group. The diﬀ erence was 
not statistically signiﬁ cant, although our study was not 
powered to detect diﬀ erences in death rate. Six children 
in the vitamin D and four in the placebo group died of 
septicaemia or pneumonia. The remaining seven deaths 
were due to accidental or congenital causes. We did not 
record any immediate or other adverse events associated 
with vitamin D3 supplementation.
The number of children lost to follow-up was low and 
many children lost at one time because of travel rejoined 
the study later with rates being similar between the two 
groups (ﬁ gure 1). There was no statistically signiﬁ cant 
diﬀ erence in any of the baseline characteristics between 
the groups (table 1), including reported sun exposure. 
Children that remained in our study had equally balanced 
characteristics. We did not identify any correlations 
between baseline variables.
On intention-to-treat analysis, the incidence of the 
ﬁ rst episode of pneumonia was greater in the vitamin D 
rather than the placebo group, although this diﬀ erence 
Vitamin D group Placebo group Incidence rate ratio 
(95% CI)
p value
Episode Person-years 
at risk
Incidence rate 
(95% CI)
Episode Person-years 
at risk
Incidence rate 
(95% CI)
Conﬁ rmed by chest radiograph
All pneumonia 260 1782 0·145 (0·129–0·164) 245 1782 0·137 (0·121–0·155) 1·065 (0·895–1·268) 0·476
Simple pneumonia 230 1812 0·126 (0·111–0·144) 219 1814 0·120 (0·105–0·137) 1·055 (0·877–1·270) 0·566
Severe pneumonia 45 1989 0·022 (0·016–0·030) 40 1990 0·020 (0·014–0·027) 1·127 (0·736–1·726) 0·579
Very severe diseases 13 2021 0·006 (0·003–0·011) 9 2018 0·004 (0·002–0·008) 1·449 (0·619–3·391) 0·389
Conﬁ rmed and unconﬁ rmed by chest radiograph
All pneumonia 1023 740 1·382 (1·299–1·469) 1030 705 1·460 (1·373–1·552) 0·953 (0·874–1·039) 0·274
Simple pneumonia 1012 817 1·238 (1·164–1·317) 997 791 1·259 (1·183–1·340) 0·985 (0·903–1·075) 0·748
Severe pneumonia 160 1847 0·086 (0·074–0·101) 149 1854 0·080 (0·068–0·094) 1·080 (0·864–1·350) 0·499
Very severe diseases 151 1899 0·079 (0·067–0·093) 167 1895 0·088 (0·075–0·102) 0·903 (0·724–1·125) 0·364
The number of child-months for those receiving at least four consecutive 3-monthly doses was 22 502 for the vitamin D group and 22 018 for the placebo group.
Table 2: Incidence rate of ﬁ rst or the only episode of pneumonia (intention-to-treat analysis)
Vitamin D group Placebo group Incidence rate ratio 
(95% CI)
p value
Episode Person-years 
at risk
Incidence rate 
(95% CI)
Episode Person-years 
at risk
Incidence rate 
(95% CI)
Conﬁ rmed by chest radiograph
All pneumonia 138 2031 0·065 (0·055–0·078) 82 2027 0·040 (0·032–0·050) 1·685 (1·282–2·212) <0·0001
Simple pneumonia 99 2031 0·047 (0·038–0·057) 51 2027 0·025 (0·019–0·033) 1·883 (1·341–2·644) <0·0001
Severe pneumonia 10 2031 0·004 (0·002–0·009) 8 2027 0·003 (0·001–0·007) 1·252 (0·494–3·173) 0·63
Very severe diseases 0 2031 0 0 2027 0 NA NA
Conﬁ rmed and unconﬁ rmed by chest radiograph
All pneumonia 2338 2029 1·152 (1·106–1·199) 2200 2025 1·086 (1·042–1·132) 1·061 (1·001–1·125) 0·04
Simple pneumonia 1945 2029 0·958 (0·916–1·001) 1825 2025 0·901 (0·861–0·943) 1·064 (0·998–1·134) 0·05
Severe pneumonia 50 2029 0·024 (0·018–0·032) 54 2025 0·026 (0·020–0·035) 0·922 (0·627–1·354) 0·68
Very severe diseases 43 2029 0·021 (0·015–0·028) 38 2025 0·018 (0·013–0·025) 1·126 (0·728–1·742) 0·59
NA=not applicable.
Table 3: Person-time at risk and incidence rate of repeat episodes of pneumonia from all sources (intention-to-treat analysis)
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was not statistically signiﬁ cant (table 2). The incidence 
rate of repeat episodes of all type pneumonia was 
signiﬁ cantly higher in the vitamin D group (table 3). 
Restricting the deﬁ nition of pneumonia conﬁ rmed with 
chest radiography to consolidation only, gave a rate of 
0·011 per child per year (95% CI 0·008–0·017) in the 
vitamin D group and 0·008 (0·005–0·013) in the 
placebo group; this diﬀ erence was not signiﬁ cant 
RR 1·44 (0·76–2·72). Extending the time between two 
consecutive episodes of pneumonia to 30 days to deﬁ ne 
a new repeat episode of pneumonia (used by the 
WHO Vaccine Trials group),19 gave similar results (data 
not shown).
The proportion of children without an episode of 
pneumonia during our 18 month study did not diﬀ er 
between the groups (ﬁ gure 2). The incidence of ﬁ rst 
episodes of simple, severe or very severe pneumonias 
conﬁ rmed with chest radiography also did not diﬀ er 
(table 1, appendix). There were very few protocol violations 
and the results of our per-protocol and post-hoc analyses 
for children getting four and ﬁ ve consecutive doses were 
not diﬀ erent from that of our intention-to-treat analysis 
(table 2, 3; appendix) A further post-hoc analysis of the 
pneumonia rates by season also did not reveal any 
diﬀ erence between the groups in our intention-to-treat or 
per-protocol analyses (data not shown).
The mean serum calcifediol concentration was consis-
tently and signiﬁ cantly higher in the vitamin D group 
than in the placebo group at 1 week, 4 weeks, and 
3 months after administration of the ﬁ rst dose of 
vitamin D during the winter and at 2 weeks’ post 
administration of dose 3 (spring; ﬁ gure 3). One child in 
the ﬁ rst sample (1 week after the ﬁ rst dose in November, 
2008) and one in the spring sample (a month after the 
second dose) of the intervention group had results greater 
than 375 nmol/L—a toxic level.6
Discussion
Our trial in a population known to be vitamin D deﬁ cient 
shows that 100 000 IU (2·5 mg) of vitamin D₃ supple-
mentation once every 3 months did not aﬀ ect the 
incidence or severity of childhood pneumonia, in this 
population. Similarly, vitamin D₃ supplementation did 
not aﬀ ect hospital admissions and all-cause mortality.
Our trial had a large sample size with a low loss to 
follow-up that remained within our sample size estimates. 
The ascertainment of study outcomes was robust, and 
done clinically through masked experienced and retrained 
paediatricians with Integrated Management of Childhood 
Illnesses clinical deﬁ nitions of pneumonia applied in 
other trials18 and radiologically through the interpretation 
of chest radiographs by masked, experienced, and external 
readers by use of WHO standards. Frequent home visits 
conﬁ rmed outcomes of interest. Supplementation raised 
the serum concentration of calcifediol in the intervention 
group at several points in our study. Thus the lack of a 
protective eﬀ ect of vitamin D against pneumonia is 
probably not due to misclassiﬁ cation of outcomes or 
inadequate supplementation. Any misclassiﬁ cation of 
other causes of raised respiratory rate as pneumonia, 
under-reporting, or over-reporting would be distributed 
equally between the two groups since the families, 
doctors, radiographers, radiologists, and data entry staﬀ  
were masked to the randomisation groupings and the 
randomisation was successful since the characteristics 
were balanced between the two groups. However, a 
limitation due to the high-risk nature of our population is 
that the generalisability of our ﬁ ndings to populations 
with low-to-moderate risk of vitamin deﬁ ciency is 
unknown. There were fewer deaths than we predicted in 
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Figure 3: Boxplot of serum calcifediol concentration
Vertical lines represent the time of supplementation, and each placebo and vitamin D pair represent a sampling 
time. Boxes are medians with IQRs. Circles represent outliers. For November and December, 2008, p<0·001; for 
February, 2008, p=0·058; for May, 2008, p<0·001; and for July, 2009, p>1·0. One child in the vitamin D group in 
January, 2008, and one in May, 2008, had serum concentrations greater than 375 nmol/L (not shown).
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both groups, possibly due to the intense health surveillance 
possible during our study. Genotyping, which was not 
practical in our study setting, might have aided the 
interpretation of our ﬁ ndings, as shown in a vitamin D 
supplementation trial for tuberculosis.20
We accounted for nutritional factors through a diet 
questionnaire, weight at recruitment, and growth 
comparison at the end of our study—any nutritional 
deﬁ ciencies would have been equally balanced between 
the two groups. As with other studies, dietary calcium 
deﬁ ciency might have led to so-called wastage of body 
stores of vitamin D in both groups, aﬀ ecting the 
maintenance of even higher vitamin D levels in the 
intervention group. Nevertheless, there was a higher 
(adequate level) mean serum concentration of calcifediol 
at the end of ﬁ rst supplementation period in the inter-
vention group compared with the lower (not adequate) 
mean concentrations in the placebo group (data not 
shown). Furthermore, adult fracture-outcome supple men-
tation studies21 show no beneﬁ t from adding calcium.
A further limitation of our study is that it was not feasible 
to undertake biochemical assessment of the supplements 
or assess serum concentrations in all participants after 
each and between supplementation. Our sample testing 
suggest that the vitamin D group maintained above mean 
adequate vitamin D concetrations verses consistently low 
concentrations in the placebo group. It can be argued that 
a steady-state adequate vitamin D concentration was not 
reached in some children because of ﬂ uctuations in serum 
concentrations due to our study regimen. Although this is 
probably true, a suﬃ  cient serum concentrations for the 
immunological eﬀ ects of vitamin D is unknown and could 
be higher or lower than that of the skeletal system accepted 
concentrations.6 The need for a steady state is currently 
highly speculative and relates to vitamin D₂ supple-
mentation for negative cancer22 and bone outcomes.23
Our ﬁ ndings are at odds with smaller case-control 
hospital studies that show an enhanced rate of vitamin D 
deﬁ ciency or rickets in children with pneumonia and 
the increasing evidence suggesting that calcitriol, the 
biologically active metabolite of vitamin D, has an impor-
tant role in the human immune system.4 A systematic 
review of the role of vitamin D supplementation in 
infectious diseases had mixed ﬁ ndings, concluding that 
more rigorously designed clinical trials are needed 
(panel).25 No studies report the eﬀ ect of vitamin D on 
radiologically conﬁ rmed pneumonias. Other trials asses-
sing infections of the upper respiratory tract also had 
mixed ﬁ ndings: one trial in post-menopausal women26 
identiﬁ ed reduced self-reported episodes of infection of 
the upper respiratory tract, speciﬁ cally in winter, whereas 
two others in elderly24 and general adults27 did not ident-
ify a diﬀ erence between the groups with regards to 
self-reported episodes. One trial in school children28 
(measuring inﬂ uenza A antigen from swabs) found a 
statistically signiﬁ cant reduced incidence in the inter-
vention group (RR 0·58, 95% CI 0·34–0·99).
The beneﬁ ts of supplementation for tuberculosis are 
similarly unclear. One paediatric trial showed 16% 
higher rates of tuberculosis symptom resolution,29 an 
adult trial showed 23% greater sputum conversion rate 
at 6 months,30 another trial showed 20% greater 
restriction of BCG-lux growth in blood,31 another trial 
found accelerated sputum conversion only in a certain 
genotype of the sample,20 whereas yet another found no 
signiﬁ cant diﬀ erence in sputum conversion32 in the 
intervention compared with the placebo group. Vitamin 
D is linked with other non-bone health outcomes, but 
the few completed and adequately powered trials 
assessing the eﬀ ect of supplementation have mixed 
ﬁ ndings in improving outcomes—ie, cancers, vascular 
disease, and diabetes. As in our studies, these 
inconsistent ﬁ ndings point to the existence of 
complicated pathways for the function of vitamin D in 
disease processes, or simply that the correct eﬀ ective 
dose of vitamin D supple mentation needs to be better 
deﬁ ned. The optimum concentrations of vitamin D for 
adults and children6 are based on non-immunological 
and, mostly, bone outcomes. An associated issue is that, 
after the start of our trial, speculations arose that high 
Panel: Research in context
Systematic Review
We searched PubMed/Medline with the terms “vitamin D supplement*”, “pneumonia”, 
“respiratory infections”, “immune*”, “cancer”, “heart disease”, and “diabetes”, 
supplemented with secondary citation (ie, assessing the references in the identiﬁ ed reports 
for more references). We did not limit our searches by language or date. No studies reported 
on radiologically conﬁ rmed pneumonias. One masked placebo trial assessed the eﬀ ect of 
bolus supplementation of vitamin D3 in a high-risk population clinically diagnosed with 
pneumonia (100 000 IU [2·5 mg] vitamin D₃ [cholecalciferol] supplementation along with 
antibiotic treatment to children younger than 3 years) in Kabul. Treatment had no eﬀ ect on 
the time to recovery but reduced the risk of clinically deﬁ ned pneumonia 13% up to 
3 months after treatment.3 Trials assessing infections of the upper respiratory tract had 
mixed ﬁ ndings: one trial in post-menopausal women24 identiﬁ ed a reduction in 
self-reported episodes of infections during winter, whereas two other studies in adults did 
not identify eﬀ ects on self-reported episodes. One trial in schoolchildren noted a 
42% reduction in the risk of inﬂ uenza A by use of antigen titre as a proxy measure. The 
reported in-vitro and case-control studies suggest a link between respiratory infections and 
vitamin D as an immunoregulator, but the evidence on the eﬀ ect of vitamin D 
supplementation on acute respiratory infections is conﬂ icting. Given that pneumonia is a 
leading cause of mortality in young children, the eﬀ ects of vitamin D supplementation to 
infants on the incidence of pneumonia merits investigation.
Interpretation
Our ﬁ ndings show that bolus quarterly supplementation of 100 000 IU vitamin D₃ did not 
reduce the rate or severity of radiologically conﬁ rmed or clinically deﬁ ned pneumonia. 
This ﬁ nding is surprising in view of evidence suggesting an association between 
vitamin D deﬁ ciency and respiratory infections. However, our ﬁ ndings are similar to some 
previous studies on the eﬀ ect of supplementation on infections of the upper respiratory 
tract or other outcomes such as bone fractures, cancers, and heart disease, and they 
contribute to the debate on factors that determine the immunological eﬀ ectiveness of 
vitamin D supplementation.
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ﬂ uctuations of natural or supplemented vitamin D 
intake might be linked to negative outcomes. These 
speculations relate two studies in which supplementation 
of a single large dose (300 00033 or 500 00023 IU) of 
vitamin D for reducing fractures in elderly women led 
to an increase in fractures, plus similar discrepancies in 
prostate cancer research with vitamin D.22 Our ﬁ ndings 
and particularly the slightly higher repeat episodes of 
pneumonia in the vitamin D group could be due to such 
ﬂ uctuations if the hypothesis is true. If so, then in terms 
of policy and guidelines, it is hard to know what regimen 
to recom mend for future trials, given that clinical 
practice and evidence suggests that daily or weekly 
supple mentations though ideal are not complied with13,14 
and are impractical for families, especially in developing 
countries, and food fortiﬁ cation at the population level 
will not be an option during exclusive breastfeeding 
periods (aged <6 months), nor is it likely to be adequate 
in highly deﬁ cient populations.
Alternately, it might be that immunological eﬀ ectiveness 
of supplementation is highly dependent upon other 
factors as yet unidentiﬁ ed, or other prevalent factors in 
this high-risk population (for example, other malnutrition 
factors and that 5·5% of the children in our study had a 
Z score of weight for age below –3). Further questions 
arise with respect to the previous treatment trial in the 
same region of Kabul, which showed that a single high-
dose supplementation with 100 000 IU vitamin D₃ given 
orally to young children, along with antibiotic treatment at 
the time of diagnosis, reduced repeat episodes of 
pneumonia in the subsequent 3 months.3 The incon-
sistent results could be related to the evidence that 
stimulation of Toll-like receptors on macrophages and 
monocytes by bacterial antigens is important in up-
regulation of CYP27B1 and the vitamin D receptor,5 which 
are crucial in production of cathelicidins in vitamin-D-
depleted individuals. In other words, this system might 
not be eﬀ ective unless there is existing infection with 
pathogens when vitamin D supple mentation is given. 
Finally, any possible reduction in the incidence of 
pneumonia in our trial might be restricted to only certain 
genotypes as recorded in a single tt genotype after the start 
of our trial in a study of tuberculosis.20 Both the pneumonia 
treatment and the population supplementation trials need 
to be repeated in other settings for conﬁ rmation, and 
frequent determi nation of serum calcifediol concentrations 
might guide the interpretation of the ﬁ ndings.
As with the trials in the older children, giving higher 
doses of vitamin D,25,34 we too did not record any adverse 
eﬀ ects associated with vitamin D supplementation. How-
ever, the number of children and the length of follow-up 
involved in these studies could only detect common and 
early adverse eﬀ ects. Although vitamin D overload is a 
theoretical possibility, 100 000 IU of vitamin D₃ has been 
shown to provide the best protection against vitamin D 
deﬁ ciency without overload or side-eﬀ ects in high-risk 
infants aged 0–9 months with normal baseline ranges of 
vitamin D.16 Furthermore, single intramuscular injection 
of three times this dose (300 000 IU) was safe in treating 
nutritional rickets in 6–30-month-old children residing 
in lower socioeconomic regions of sunny Istanbul.35 
Higher than recommended doses of daily supplementation 
of vitamin D (500–1000 IU per day, adding up to 
120 000 IU over 3 months) plus additional milk fortiﬁ ed 
with vitamin D, has been shown not to induce an 
overload,13 including in infants starting with normal 
ranges of vitamin D, even when supplementation 
continued during the summer (in France) and when 
mothers had antenatal vitamin D supplementation.36 It is 
important to note that in our study, where community 
supplementation was in a population with known high 
rates of vitamin D deﬁ ciency, 1% of children tested had a 
calcifediol concentration greater than 375 nmol/L—
thought undesirably high.6 Although these did not 
produce any clinical signs and symptoms, these 
measurements raise a need for caution with doses for 
population supplementation. The speculative negative 
role of ﬂ uctuations is vitamin D needs to be considered 
with caution until further evidence is available.
We have shown that a quarterly 100 000 IU supple-
mentation of vitamin D3 did not reduce the incidence of 
pneumonias in children living in regions with high vitamin 
D deﬁ ciency. In populations with similar characteristics, 
quarterly population level supplemen tation of vitamin D to 
infants and young children is not a policy option for 
reducing the burden of pneumonia in children.
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